About Cibeles Pharmaceuticals Private Limited
Data last updated:
Cibeles Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Bdr Pharmaceuticals International Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 May 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24100MH2019PTC379982. Its GSTIN is 27AAICC1632P1ZD (Maharashtra). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹22.32 Cr. It is led by directors including Sainath Vramarathnam Iyer and Trushit Pramodray Mehta.
Its last annual general meeting (AGM) was held on 27 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹27.15 Cr, a growth of 48% compared to the previous year. For the same year it recorded a net loss of ₹9.15 Cr (net margin -33.7%) and EBITDA of -₹9.2 Cr (EBITDA margin -33.9%). Revenue has grown at a compounded annual rate (CAGR) of 35% over three years and 109% over five years.
The company is associated with 1 brand: Cibeles. The company has 4 deals on record (2 rights issues, 1 secondary share transfer, 1 funding round), with disclosed funding of ₹3.99 Cr; the latest was in April 2022. The company has 9 MSME Form 1 returns on record between 2020 and 2023, listing 121 overdue payments to 13 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cibeles.com.
Company details
CIN history
Cibeles Pharmaceuticals has one previous CIN (Corporate Identification Number): U24100KA2019PTC124043. The current CIN is U24100MH2019PTC379982, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100MH2019PTC379982 | Current |
| U24100KA2019PTC124043 | Previous |
Contact details
Cibeles Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra. Its website is cibeles.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressG.16 Mahalaxmi Woolen Mill Compound Opp. Shakthi Mill Compound Dr. E Mosses Road Mahala, Xmi, Mumbai, Maharashtra, India – 400012
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cibeles Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Cibeles Pharmaceuticals operates one associated brand: Cibeles. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical manufacturing, distribution, and employee-focused services in India. | cibeles.com |
Business activity
The main business activity of Cibeles Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Cibeles Pharmaceuticals Private Limited, buy the company report.
Financials of Cibeles Pharmaceuticals Private Limited
FY 2024 filings availableCibeles Pharmaceuticals Private Limited reported revenue of ₹27.15 Cr (up 48% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 109% over five years, including 48% growth in the latest year. EBITDA fell 50% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹9.2 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹9.15 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -33.9% | ||||
| Net Profit Margin | -33.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cibeles Pharmaceuticals Private Limited, buy the company report.
Board of directors of Cibeles Pharmaceuticals Private Limited
Cibeles Pharmaceuticals has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Trushit Pramodray Mehta | Nominee Director | 03 Mar 2020 | 6 Years 8 Months | Current |
| Sainath Vramarathnam Iyer | Director | 22 Oct 2019 | 7 Years 0 Months | Current |
| Dheer Dharmesh Shah | Nominee Director | 03 Mar 2020 | 6 Years 8 Months | Current |
Auditor
Cibeles Pharmaceuticals Private Limited is audited by SGDG & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SGDG & Associates LLP | FY 2023 | W100188 |
Shareholding
The shareholding of Cibeles Pharmaceuticals Private Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Cibeles Pharmaceuticals Private Limited, buy the company report.
Deals & funding
Cibeles Pharmaceuticals Private Limited has 4 deals on record (2 rights issues, 1 secondary share transfer, 1 funding round), with disclosed funding of ₹3.99 Cr; the latest was in April 2022.
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2022 | Rights issue | ₹3.94 Cr | Investors: BDR Pharmaceuticals International Private Limited , an individual |
| Oct 2020 | Rights issue | ₹6.94 Cr | Investors: BDR Pharmaceuticals International Private Limited , an individual |
| Oct 2019 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Tenshi Life Sciences Private Limited , Hydra Active Pharma Sciences Private Limited |
| Jul 2019 | Funding round | ₹3.99 Cr | Investors: BDR Pharmaceuticals International Private Limited , Tenshi Life Sciences Private Limited , an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Cibeles Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Cibeles Pharmaceuticals Private Limited has 9 MSME Form 1 returns on record between 2020 and 2023, listing 121 overdue payments to 13 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 13)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Trimurti Cars Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Ibis Systems and Solutions Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Cibeles Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Cibeles Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAICC1632P1ZD | Maharashtra | Active | 05 Dec 2019 |
To see the full GST registrations and return filing status of Cibeles Pharmaceuticals Private Limited, buy the company report.
Recent activity
Cibeles Pharmaceuticals Private Limited has 7 board changes on record since 2019: 3 appointments and 4 cessations. The latest: Dheer Dharmesh Shah was appointed as Nominee Director on 03 Mar 2020.
Frequently asked questions
Cibeles Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 May 2019 (7+ years old) and is registered under CIN U24100MH2019PTC379982.
Cibeles Pharmaceuticals has 3 current directors:
- Trushit Pramodray Mehta - Nominee Director
- Sainath Vramarathnam Iyer - Director
- Dheer Dharmesh Shah - Nominee Director
The latest financial statements of Cibeles Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 27 September 2024. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Cibeles Pharmaceuticals is 27AAICC1632P1ZD, registered in Maharashtra. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Cibeles Pharmaceuticals is U24100MH2019PTC379982. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cibeles Pharmaceuticals was incorporated on 03 May 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Cibeles Pharmaceuticals has 4 deals on record (2 rights issues, 1 secondary share transfer, 1 funding round), with disclosed funding of ₹3.99 Cr; the latest was in April 2022.
Dheer Dharmesh Shah was appointed as Nominee Director on 03 Mar 2020. Trushit Pramodray Mehta was appointed as Nominee Director on 03 Mar 2020. Tejash Vijay Shah ceased to be Director on 20 Feb 2020. Cibeles Pharmaceuticals has 7 board changes on record in total.
Cibeles Pharmaceuticals has 9 MSME Form 1 returns on record between 2020 and 2023, listing 121 overdue payments to 13 micro and small suppliers. The latest return was filed on 17 Nov 2023.
Cibeles Pharmaceuticals can be reached through the website cibeles.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Cibeles Pharmaceuticals is at G.16 Mahalaxmi Woolen Mill Compound Opp. Shakthi Mill Compound Dr. E Mosses Road Mahala, Xmi, Mumbai, Maharashtra, India – 400012.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
